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Lysosomes, since their discovery, have been primarily known for degrading cellular macromolecules. However, in recent studies,
they have begun to emerge as crucial regulators of cell homeostasis. They are at the crossroads of catabolic and anabolic pathways
and are intricately involved in cellular trafficking, nutrient signaling, energy metabolism, and immune regulation. Their involvement
in such essential cellular functions has renewed clinical interest in targeting the lysosome as a novel way to treat disease,
particularly cancer. Acute myeloid leukemia (AML) is an aggressive blood cancer with a low survival probability, particularly in older
patients. The genomic landscape of AML has been extensively characterized but few targeted therapies (with the exception of
differentiation therapy) can achieve a long-term cure. Therefore, there is an unmet need for less intensive and more tolerable
therapeutic interventions. In this review, we will give an overview on the myriad of functions performed by lysosomes and their
importance in malignant disease. Furthermore, we will discuss their relevance in hematopoietic cells and different ways to
potentially target them in AML.
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INTRODUCTION
History and renewed interest
Lysosomes were first discovered by Christian de Duve in 1955
while working on a specific enzyme, glucose-6-phospatase, a
target of insulin in hepatic tissue. Glucose-6-phosphatase was
found to be encased in what was described as “sac-like particles”
[1]. Several more pH sensitive hydrolases were then discovered in
the same fraction of the cell and within a few years, the role of
lysosomes in the digestion of extra- and intra-cellular material was
established.
In the 1990s, the discovery of autophagy [2], generated a
new appreciation for lysosomes as a degradative organelle
critical for cellular recycling and homeostasis. However, as
the final step in autophagic flux, lysosomes still lacked prestige
due to their relegation to garbage disposal units. More
recent studies have now elevated the lysosome to center
stage with a new understanding of their role as a sensor of
cell stress and coordinator of the response to a diverse range of
environmental cues including nutrient, growth factor, and
immune-related signaling [3, 4]. With that, clinical interest
in the organelle for therapeutic intervention has also re-
emerged [5].
In this review, we will focus on the key signaling functions of
lysosomes, their potential role in the pathophysiology of
malignant disease and consider why lysosomes might represent
a good therapeutic target for acute myeloid leukemia (AML).
Overview of lysosome function, biogenesis, and interaction
with other organelles
Lysosomes are acidic organelles with an internal pH of 4.5 to 5.5,
maintained by the presence of the vacuolar-type H+ATPase
(V-ATPase) on the lysosomal membrane [6]. This pH range allows
luminal hydrolytic enzymes, which degrade macromolecules, to
function optimally. Lysosomes are heterogeneous in morphol-
ogy, distribution, and function depending on the species and
cell type. They can rapidly change their distribution, number,
size, and activity to meet cellular needs. The formation of
primary lysosomes requires fusion between endosomes and
Golgi-derived vesicles containing hydrolytic enzymes tagged for
lysosomal delivery [7].
The outer lysosomal membrane is rich in transmembrane
proteins, predominantly lysosome-associated membrane proteins
(LAMPs). Five types of LAMPs have been identified so far: LAMP-1/
CD107a, LAMP-2/CD107b, LAMP-3/DC-LAMP, LAMP-4/Macrosialin/
CD68 and LAMP-5/BAD-LAMP. LAMP-1 and LAMP-2 account for
almost 80% of the lysosomal membrane proteins. Other key
lysosomal membrane proteins (LMPs) include, ion channels and
various receptors for specific cargo, tethering/fusion or signaling,
such as the chloride channel protein 7 (CLC7), Niemann-Pick
C1 protein (NPC1), synaptotagmin (SYT7), and the Vacuolar
(V)-ATPase proton (H+ ) transporter [8].
Lysosomal genes are transcriptionally co-regulated in a
network of genes referred to as the CLEAR network (Coordinated
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Lysosomal Expression and Regulation)—enabling a rapid response
to metabolic demand. This gene network is regulated by
transcription factors belonging to the microphthalmia/transcrip-
tion factor E (MiT/TFE) family, including TFEB, TFE3, and MITF. They
bind to a 10-bp palindromic motif sequence in the promoter
sequence of lysosomal genes referred to as the CLEAR element.
TFEB has also been shown to co-regulate the expression of several
autophagy genes [9].
Lysosomes are the terminal compartment for the delivery of
cargo from clathrin- and caveolin-dependent and -independent
endocytosis, autophagosomes, phagosomes, and chaperone-
mediated autophagy (CMA) (Fig. 1). Interaction and fusion with
other organelles are regulated by specific GTPases, Soluble N-
éthylmaleimide-sensitive-factor Attachment protein REceptor
(SNARE) complexes and Ca2+ release from the lumen of the
lysosome [10]. The primary role of lysosomal fusion is considered
to be degradation of internal or external cargo into products that
can be exported back to the cytoplasm for metabolic reuse, or in
the case of professional antigen-presenting cells (APCs), presented
as peptides by major histocompatibility complex (MHC) molecules
to instigate an immune response [11]. However, fusion events,
cargo components or contact with other ligands or organelles can
also trigger signaling events [12].
Signaling events arising from the intra-luminal compartment
The luminal compartment of lysosomes is the hydrolytic engine of the
organelle, containing more than 60 acidic hydrolytic enzymes
including proteases, nucleases, lipases, glycosidase phosphatases,
and sulfatases. Deficiencies in any of these enzymes can have a major
impact on cellular homeostasis. The lysosome is also a reservoir for
important ions and metabolites including Ca2+ /Fe2+ /Zn2+ , H+ /
Na+/K+, Cl-, and ATP. Intra-luminal levels of amino acids such as
arginine and leucine are also regulated by lysosomal receptors and
linked to external signaling [13].
Degradative enzymes and lysosome-dependent cell death. Cargo
digestion is a key function of lysosomal enzymes. Several classes
of enzymes will however also influence events outside the
lysosome. Cathepsins are lysosomal proteases classed into, serine
(A and G), aspartic (D and E), and cysteine proteases (B, C, F, H, K L,
O, S, V, W, and X). The release of these proteases into the
extracellular space has been associated with degradation of the
extracellular matrix, cell migration, and invasion of cancer cells
[14]. In addition, the release of proteases following lysosomal
membrane leakage has been associated with cell death [15].
Several forms of lysosomal cell death (LCD) have now been
described. Cells may exhibit necrotic, apoptotic, or apoptosis-like
features depending on the extent of the leakage and the cellular
context [16].
Lysosomes and calcium signaling. Lysosome membranes contain
several ion channels that establish concentration gradients and
maintain the lysosome membrane potential (ΔψLysol). Relative to
the cytoplasm, the lysosome has high concentrations of Ca2+ ,
Fig. 1 Main functions of lysosomes: Endosomal trafficking and autophagy pathways. Lysosomes are the terminal organelle for endocytic
and autophagic pathways. External cargos are delivered to lysosomes via clathrin- and caveolin-dependent pathways or receptor-
independent pathways such as phagocytosis. Late endosomes can either fuse with lysosomes, or they can release their contents outside the
cell via extracellular vesicles known as exosomes. Cytoplasmic cargos are delivered to lysosomes for degradation by autophagosomes
(macroautophagy), with the help of heat shock protein (HSP) A8 chaperone complex (CMA) or simply by invagination of the lysosomal
membrane itself followed by engulfment (microautophagy). Created with BioRender.com.
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which is a key regulator of many lysosomal functions. There are at
least three main types of Ca2+ channels in mammalian lysosomes:
Transient receptor potential mucolipin sub-family (TRPML)/muco-
lipin 1-3, (Two-Pore) TPC1-2 and P2X4. These respond to a variety
of signals including cell stress, phospholipids, nutrients, and ATP
depletion. The best-characterized channel is probably TRPML1/
mucolipin 1, which regulates several lysosomal processes includ-
ing lysosomal reformation, exocytosis, motility, and fusion with
other organelles. Calcium efflux from TRPML1 also activates the
calcium-dependent phosphatase calcineurin, which is important
for TFEB nuclear translocation [17].
Luminal essential amino acid (EAA) sensing role. The lysosome can
sense both luminal and cytosolic amino acid levels—with crosstalk
between these pathways to maintain homeostasis or respond to
nutrient-related signaling. Lysosomal luminal arginine is sensed by
the sodium-coupled amino-acid transporter SLC38A9. The binding
of arginine induces a conformational change in SLC38A9 leading
to stimulation of the Rag A/B (Ras-related GTP-binding) GTPase
and Ragulator complex localized on the lysosomal surface. This
recruits the mechanistic target of rapamycin complex 1 (mTORC1),
which is one of two protein kinase complexes incorporating the
serine-threonine kinase mTOR. The mTORC1 complex consists of
the mTOR kinase itself, Raptor, GβL, and DEPTOR. mTORC1 is then
activated by Rheb (Ras homolog enriched in brain) GTPase, on the
lysosomal membrane. Simultaneously, SLC38A9 also allows efflux
of other amino acids such as leucine into the cytosol. This enables
cross talk with other cytosolic amino acid sensors associated
with mTORC1 complex (outlined below) [13, 18]. High levels of
intra-luminal leucine can also activate mTORC1 by promoting ATP
hydrolysis by the V-ATPase. This also stimulates the Ragulator/Rag
complex to recruit mTORC1 [19] (Fig. 2).
The lysosome surface as a signaling hub
As with other organelles, most intra-organelle communication and
signaling is orchestrated at the surface. The lysosomal surface is a
platform for the assembly of several signaling hubs that link
metabolic functions to environmental signaling. A central link in
this signaling is the mTORC1 complex. The primary role of active
mTORC1 is to drive anabolic/biosynthetic pathways to fuel growth
and proliferation and to inhibit catabolic pathways such as
autophagy. Several signaling cues converge at mTORC1 including
(i) nutrients (ii) growth factors and (iii) energy status.
Cytosolic amino acid signaling. Amino acids promote the translo-
cation of mTORC1 to the lysosomal surface where it can be
activated. This process is mediated by the coordinated actions of
several complexes including Ragulator and Rag GTPases (A, B, C, and
D). The Ragulator complex consists of 5 subunits; p18, p14, MP1,
C7orf59, and HBXIP (also referred to as LAMTOR -1, 2, 3, 4, 5
respectively). The p18 subunit (LAMTOR-1) is anchored to the
lysosomal membrane. In response to amino acids, Ragulator acts as
a guanine nucleotide exchange factor (GEF) for Rag A/B—promoting
their GTP bound state and anchoring both the Rag GTPases and
mTORC1 to the membrane where it can be activated by the small
GTPase Rheb [20, 21].
The presence of specific amino acid residues also influences other
GEFs and GTPase-activating proteins (GAPs), upstream of GTP-RagA
Fig. 2 External and internal signaling events on the surface of lysosomes. Lysosomal membranes harbor a variety of proteins that regulate
multiple signaling pathways. The transporter protein NPC1 releases free cholesterol from the lumen to maintain lipid homeostasis. The
V-ATPase is a proton pump responsible for maintaining luminal pH. mTORC1 links metabolic functions to environmental signaling.
The components of the mTORC1 signaling pathway can be regulated by both intra- and extra-luminal amino acid signaling. Arginine (R) in the
lysosomal lumen is sensed by the amino acid transporter SLC38A9 which eventually activates mTORC1 with the help of the Rag GTPases and
Ragulator complex. In the cytosol, Sestrin proteins serve as leucine (L) sensors and with the help of GATOR proteins, regulate mTORC1 activity.
See text for further description. mTORC1 also negatively regulates lysosome biogenesis. Luminal Ca2+ initiates lysosome biogenesis. It is
released into the cytoplasm through the lysosomal calcium channel TRPML1 to activate calcineurin, which dephosphorylates TFEB, enabling it
to translocate into the nucleus where it facilitates transcription of the CLEAR network genes. This pathway is inhibited by the transcription
repressor ZKSCAN3. LAMPs are transmembrane proteins that account for about 80% of all membrane proteins and take part in various
functions including, autophagy, lipid transport, and immune response. SYT7 is another calcium-dependent membrane protein that takes part
in lysosomal exocytosis. Created with BioRender.com.
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and GDP-RagC and mTORC1 signaling. A key integrator of amino
acid signaling is the GTPase-activating proteins toward Rags
(GATOR) complex [22]. GATOR is composed of two sub-complexes:
GATOR1 and GATOR2. GATOR1 acts as a GAP (off switch) for RagA/B,
releasing mTORC1 from the lysosome, thus acting as a negative
regulator. GATOR2 positively regulates mTORC1 by inhibiting the
GAP activity of GATOR1. Leucine and arginine residues act through
stress-inducible proteins (Sestrins) and cytosolic arginine sensors for
mTORC1 subunit 1 (CASTOR1) respectively. Upon amino acid
binding, they dissociate from GATOR2, releasing their suppressive
effects on GATOR2 and activate mTORC1 [23]. In the absence of
amino acids, mTORC1 activity is also regulated by the cyclin-CDK
inhibitor, cyclin-dependent kinase inhibitor 1C (CDKN1B) or p27. It
binds to LAMTOR1 and prevents mTORC1 activation, which in turn,
activates macroautophagy. In this context, p27 serves as a tumor
suppressor [24].
Growth factors. Many external signals, such as growth factors
converge at a large protein complex referred to as tuberous
sclerosis complex (TSC), which negatively regulates the MTORC1
kinase [25]. TSC is a complex of TSC1, TSC2, and TBC1D7 subunits.
TSC2 displays GTPase-activating protein (GAP) activity for Rheb,
inactivating Rheb through induction of the GDP-bound state.
Initially, signaling from receptors such as insulin or IGF (insulin-like
growth factor) generates phosphatidylinositol lipids (3,4,5)P3
(PIP3), which stimulates protein kinase B (Akt) phosphorylation
and inactivation of TSC2. This inactivation leads to an increase in
GTP-loaded Rheb, which fuels activation of mTORC1 [26].
Energy status. In contrast to growth factor signaling, energy
depletion activates AMP kinase at the lysosomal surface, which
stimulates TSC2 through phosphorylation and inhibits RAPTOR.
This leads to inhibition of mTORC1 and promotion of catabolic
pathways [25].
mTORC1 and transcriptional regulation of anabolic/catabolic
pathways
mTORC1 also plays a major role in the phosphorylation of MiT/TFE
factors. Under nutrient-rich conditions, mTORC1 phosphorylates
TFEB on Ser 122 and Ser 211 and sequesters it to the cytoplasm.
Inhibition of mTORC1 under a stressful condition, such as
starvation, disrupts this association allowing nuclear translocation
of TFEB and transcription of CLEAR network genes [3]. Another
important regulator of TFEB nuclear translocation is the
Ca2+ -dependent phosphatase, calcineurin. During starvation,
Ca2+ is released through the lysosomal calcium channel,
TRPML1/mucolipin-1, activating calcineurin, which dephosphor-
ylates TFEB. A zinc finger family DNA-binding protein, ZKSCAN3,
has been shown to be a transcriptional repressor of autophagy by
repressing the expression of more than 60 essential genes
associated with lysosomal biogenesis and autophagy including
Microtubule Associated Protein 1 Light Chain 3 Beta (Map1lc3b) and
Wipi2. ZKSCAN3 and TFEB have also been found to be oppositely
regulated by starvation [27] (Fig. 2).
Autophagy
Autophagy is a process by which cells transport dysfunctional or
excessive cellular components into the lysosomes for degradation.
Autophagy can eradicate harmful organelles, pathogens or
aggregated material and the recycling of macromolecules from
the lysosome enables cells to cope with stresses such as nutrient
deficiency [28]. The three main types of autophagic pathways are
macroautophagy, microautophagy and chaperone-mediated
autophagy.
Macroautophagy is mediated by several protein conjugation
reactions, eventually leading to the formation and expansion of a
double-membraned autophagosome which carries the cargo to
the lysosome to be degraded [29]. The genes involved in the
process are known as ATG (AuTophaGy-related) genes, first
identified in yeast, followed by studies of orthologues in other
species [30]. In mammals, macroautophagy is initiated through
activation of two key upstream regulatory complexes: (i) The class
III phosphatidylinositol 3-kinase (PI3K-III/ VPS34) complex containing
Beclin-1 (a mammalian homolog of yeast Atg6), hVps34, p150 (a
mammalian homolog of yeast Vps15), and Atg14-like protein
(Atg14L) and (ii) the ULK1 kinase complex (ULK1-Atg13-FIP200-
ATG101)—this activates the class III PI3K/ Beclin-1 complex
enabling autophagosome nucleation. These complexes are
regulated by phosphorylation from the following pathways:
The PI3K/AKT/mTOR signaling pathway: Under abundant supply
of nutrients and growth factors, cells activate the PI3K/AKT/mTOR
signaling pathway and suppress autophagy, by inhibitory
phosphorylation. In contrast, when cells are experiencing stress
or nutrient starvation, they respond by inactivating the PI3K/AKT/
mTOR pathway, which de-represses and activates autophagy.
The AMPK signaling pathway: AMPK (AMP-activated Protein
Kinase) is a critical energy-sensing protein, which detects changes
in the ratio of ATP to AMP or ADP. Phosphorylated AMPK
phosphorylates TSC2 thereby inhibiting mTORC1 and activating
autophagy. AMPK can also induce autophagy by directly
phosphorylating and activating ULK-1/2. [31]
CMA is a client-specific, selective autophagic pathway. CMA
clients contain a signature motif containing a short stretch of 5
amino acid residues, KFERQ (Lysine, Phenylalanine, Glutamate,
Arginine, Glutamine) [32]. This motif is recognized by the
chaperone protein HSPA8, also known as HSC70 or HSP73, which
is a member of the HSP70 family of proteins [33]. The client
protein is received on the lysosomal surface by a single molecule
of LAMP-2A. LAMP-2A receptors form multimers that are stabilized
by HSP90 on the lysosomal surface and aid translocation of the
client. HSPA8 is also present inside the lysosome and helps in the
translocation of the substrate by interacting with LAMP-2A [34].
In microautophagy, the dynamics of the lysosomal membrane
allows it to wrap itself around cytosolic contents and engulf them
into the lumen for degradation. Molecular details of microauto-
phagy have not been elucidated as thoroughly as the other two
pathways. Client specificity has been reported in endosomal
microautophagy. Similar to CMA, the protein clients harbor a
KFERQ-like motif and are delivered to the lysosomes by HSPA8
with the help of the endosomal sorting complex required for
transport (ESCRT) machinery [35]. The ESCRT machinery helps to
load protein into multivesicular bodies (MVBs), which are a special
form of late endosome, that can then fuse with the lysosome [36].
Subcellular localization of lysosomes
The signaling properties of lysosomes are affected by their
position within the cell. Lysosomes can move from the center of
the cell to the periphery or vice versa with the help of kinesin
motors KIF2A and KIF1Bβ as well as the small GTPase ARL8B [37].
The consequences of lysosomal positioning seem to be depen-
dent on the environmental signaling. Localization of lysosomes
towards the periphery has been associated with increased
interaction with mTORC1 and elevation of mTOR activity, whereas
perinuclear localization in starved conditions inhibits mTORC1 and
activates autophagy [38]. Hong and colleagues have shown that
mechanistically, the FYVE-domain proteins Protrudin and FYVE
and coiled-coil domain autophagy adaptor 1 (FYCO1) help to
bring mTOR positive lysosomes towards the plasma membrane in
a VPS34-dependent process [39]. Perinuclear clustering also delays
mTORC2 reactivation in response to serum depletion [40]. In
contrast, it has also been reported that under hypoxic conditions,
lysosomes localize to the periphery and this actually reduces
mTORC1 activity [41]. The tumor suppressor, folliculin is respon-
sible for the association of lysosomes with the perinuclear
membrane and restricting their localization in the area [42]. The
subcellular localization of lysosomes also determines their luminal
S. Rafiq et al.
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pH. Peripheral lysosomes are less acidic due to lowered V-ATPase
activity [43]. The movement of lysosomes within the cell is
essential for lysosomal exocytosis, which is a process that leads to
the secretion of lysosomal content upon lysosome fusion with the
plasma membrane. It is a ubiquitous, Ca2+ -regulated mechanism,
which plays a role in various physiological processes such as,
plasma membrane repair and immunogenic ATP release [44].
Galectins and lysophagy
The elimination of defective lysosomes by autophagy is referred to
as ‘lysophagy’. Several β-galactoside-binding proteins (galectins)
have been implicated in mediating lysophagy. GAL 3, 8 and 9 are
recruited by exposure of luminal glycans following lysosomal
damage. Galectin 8 can inhibit mTORC1 and Galectin 9 activates
Mitogen-activated protein kinase kinase kinase 7 (TAK1 or
MAP3K7) that stimulates AMPK [45]. Members of the galectin
family have also been implicated in the control of differentiation
and self-renewal of hematopoietic cells [46], and have been
associated with prognosis in AML [47].
Lipid homeostasis
Lysosomes are important regulators of lipid homeostasis and play
a key role in cholesterol trafficking [48]. Low-density lipoproteins
(LDLs) are trafficked to lysosomes via clathrin-mediated endocy-
tosis. The release of free cholesterol from the lysosome is
mediated by two transporter proteins, NPC 1 and 2 [49].
Lysosomes also contribute to maintaining cellular lipid balance
through a selective autophagy pathway, referred to as lipophagy.
Lipids are stored as triglycerides in lipid droplets (LD) which are
delivered to lysosomes via lipophagy and degraded to release free
fatty acids (FFAs) that can be used as an energy source [50].
Immune responses/inflammation
Lysosomes can participate at several stages in the generation of
an immune response. This includes pathogen sensing, phagocy-
tosis, antigen processing and presentation, and inflammation/
secretion.
Sentinel cells such as macrophages and dendritic cells (DCs)
use toll-like receptors (TLR) to sense pathogens and elicit an
immune response. Members of the TLR family, TLR 3 TLR7, TLR 8,
and TLR9 have been shown to signal from endolysosomes. In
addition, TLR9 responds to mitochondrial DNA, delivered to the
lysosome via mitophagy [51, 52]. Foreign particles are internalized
by phagosomes which eventually mature and fuse with
lysosomes to become phagolysosomes. TFEB enhances phago-
cytosis in a calcium-dependent manner by transcriptional
activation of immune-related genes [53]. Macrophages, DCs,
and B cells are APCs that process antigens from degraded
pathogens and incorporate them into MHCs on their surfaces.
Lysosomal pH is important in this process as too much
acidification results in excessive proteolysis of engulfed microbes,
thus impairing cross-presentation. On the other hand, increased
lysosomal pH can also alter lysosomal properties and impair
antigen processing as seen in lupus, for example [54]. Lysosomes
also participate in downregulation of inflammation in immune
cells. The inflammasome complex, which is responsible for the
secretion of pro-inflammatory cytokines such as IL-1β and IL-18, is
selectively degraded via autophagy [55, 56]
Fig. 3 Various ways to modulate lysosomes and their functions. Lysosomes are associated with various pathways which makes it possible to
target them in different ways. Lysosomotropic agents can disrupt the lysosomal membrane and release cathepsins into the cytosol leading to
LCD. Other lysosomotropic agents such as chloroquine (or hydroxychloroquine) can impede lysosomal membrane fusion which is important
for turnover in autophagy. Due to the protective role of HSP70 against lysosomotropic agents, HSP70 inhibitors can be used to intensify their
effect. During oncogenic activation, lysosomal exocytosis causes release of cathepsins into extracellular space, which promotes extracellular
matrix degradation and invasion of malignant cells. This makes protease inhibitors targeting cathepsins also a therapeutic option. Autophagic
pathways have context-dependent roles in cancer and thus, there may be several strategies to either block or stimulate the pathways.
Upstream pathways such as mTORC1 and 2 can be inhibited to stimulate autophagy in an indirect manner. V-ATPase inhibitors can elevate
lysosomal pH, thus impairing the function of many pH-sensitive lysosomal enzymes. Created with BioRender.com.
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LYSOSOMES IN MALIGNANCY
Cell transformation and cancer progression require an increase in
biomass production and adaptation to nutrient stress, processes
that are aided by lysosomes. Accordingly, cancer cells have
higher lysosomal activity compared to healthy adjacent tissue
[57]. Lysosomes contribute to the maintenance of many
hallmarks of cancer such as, sustaining proliferative signaling
(mTORC1 signaling), metabolism (catabolic reactions, autop-
hagy), and invasion (lysosomal exocytosis) [58]. For example, in
sarcomas, downregulation of the protein NEU1 aggravates
lysosomal exocytosis, which releases hydrolases and exosomes
that facilitate extracellular matrix remodeling and invasion into
the adjacent tissue [59]. Lysosomes are also known to sequester
chemotherapeutic drugs and thus play an active role in the
development of drug resistance [60]. In addition, lysosomes in
metastatic cells differ greatly in content, localization, and activity
from the lysosomes in normal cells which make them potentially
more susceptible to lysosome targeting agents [61]. Since
lysosomes are central to many cellular pathways, several ways
exist to target them indirectly for cancer therapy (Fig. 3).
Direct impairment of lysosomal function can be achieved
through several strategies. Most of the therapeutic agents being
developed to target lysosomes either raise the luminal pH to
inactivate cathepsins thus rendering them unable to mediate
invasion, or aid in lysosomal membrane permeabilization and
induce LCD. Lysosome targeting agents and the diseases they are
being tested against has already been adequately reviewed [62].
In Table 1, we have summarized the mechanism of a few
emerging preclinical options which can affect lysosomes, the
diseases they have been tested with, and their toxicity profile.
LYSOSOMES IN AML
Hematopoiesis is a complex process that gives rise to cells with
strikingly distinct morphology and functions. Such processes
require drastic reorganization of cellular homeostasis. Lysosomes
play a vital role here as they maintain a balance between anabolic
and catabolic pathways. Due to their association with the master
regulator of cell growth, mTORC1, and the ability to degrade
macromolecules via autophagic pathways, they are in a central
position to modulate metabolism, differentiation, proliferation,
and cell death. All of these components are essential in the
maintenance of functioning hematopoiesis and their dysregula-
tion can be a feature of hematological malignancies.
Lysosome derived structures in myeloid leukemia cells
Auer rods (or Auer bodies) are large structures sometimes
observed in AML, acute promyelocytic leukemia (APL), and
myelodysplastic syndromes (Fig. 4). Auer rods are azurophilic,
can resemble needles, commas, diamonds, rectangles, corkscrews,
and can appear bundled. They are not always present—but are a
highly specific finding and virtually pathognomonic for a myeloid
neoplastic disorder. They are apparently composed of fused
lysosomes and are rich in lysosomal enzymes. Their method of
formation and functional significance are not known but several
processes have been described that cause tubulation of lysosomes
including autophagic lysosome reformation (ALR) [63] and
activation of antigen-presenting cells. Activation of macrophages
and DCs causes dramatic tubulation of endolysosomes—which
increases their surface area to volume ratio and is also proposed
to assist with the delivery of MHC-II peptides to the cell surface for
presentation [64].
In positive AML cases, the percentage of cells with Auer rods
and the number of Auer rods per cell can vary greatly. Auer rods
are found in AML M1, M2, M3, M4, M5, and M6, but not in AML M0
or M7 of the French–American–British (FAB) classification, or in
blast crisis chronic myeloid leukemia, suggesting an association
with a more mature myeloid phenotype. While Auer rods clearly
have diagnostic value in determining the neoplastic nature of
myeloid cells, they do not seem to have a clear prognostic
significance [65].
Lysosomes in hematopoietic stem cells (HSC)
HSC are responsible for repopulating blood cells and maintaining
blood homeostasis. Therefore, in order to protect themselves from
stress, they usually remain quiescent. Liang et al., reported that,
quiescent HSCs are defined by their low mitochondrial membrane
potential and glycolysis. Enlarged lysosomes are found in
quiescent HSCs, which are speculated to remove toxic products
and contribute to the maintenance of healthy HSCs [66].
Lysosomes are asymmetrically inherited by the daughter cells
during cell division of HSCs and therefore determine their cellular
fate by reorganizing the metabolic and translational machinery of
the cells [67].
Autophagy in HSCs
Autophagic pathways, in particular, macroautophagy contributes
to the maintenance of energy metabolism, which is crucial in
HSCs. The transcription factor FOXO3A, drives a gene expression
program that induces autophagy to protect HSCs during stress
[68]. The specific knockout of Atg7 in the hematopoietic system of
mice results in severe clinical symptoms (lethargy, piloerection,
and weight loss), leading to their death within 12 weeks. The
Atg7−/− LSK (Lin− Sca-1+ Kit+) cells showed accumulation of
mitochondria and DNA damage with complete loss of stem cell
function [69]. Similar pre-leukemic phenotypes were observed in
Atg5 knockout mice [70]. FIP200, a key protein in the autophago-
some nucleation process, is necessary for fetal HSC maintenance
and its loss leads to a block in erythroid maturation, depletion, and
loss of reconstituting capacity of HSCs, and aberrant expansion of
myeloid cells [71]. A recent study reported that CMA is crucial for
protein quality control and metabolic reprogramming during HSC
activation. It also maintains the functionality of aged HSCs [72].
Autophagy in AML
Autophagy dysregulation can lead to and drive AML. An in silico
analysis has shown that a deleted chromosomal region often
found in AML coincides with the location of autophagy genes and
that lowered autophagic flux is advantageous to AML [70].
Heterozygous deletion of Atg5 in Mixed Lineage Leukemia-
Fig. 4 Auer Rods. Image of acute promyelocytic leukemia (APL)
blast cell. Black arrow heads indicate bundles of needle-shaped Auer
rods. See text for further description. (Courtesy: Myriam Legros,
Center of Laboratory Medicine, University Hospital Bern). Informed
consent is available for all patients in oncology.
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Eleven Nineteen Leukemia (MLL-ENL) induced murine HSCs led to
a higher proliferation rate and a more aggressive leukemia in vivo
due to a shift towards glycolytic metabolism [70]. Depletion of
ATG7 was found to enhance chemoresistance in mice trans-
planted with OCI-AML3 cells harboring Atg7 targeting shRNA [73].
In a MLL-AF9 driven model, deletion of Atg5 accelerated the
initiation of leukemia but had no effect on therapeutic interven-
tion [74]. Conversely, another study on MLL-ENL leukemic mice
showed that homozygous deletion of Atg5 or Atg7 in bone
marrow cells reduced the frequency of leukemia-initiating cells
(LICs) and decelerated leukemia progression [75]. In FLT3-ITD
driven AML, the receptor tyrosine kinase, RET, has been identified
Fig. 5 Role of lysosomes in hematopoiesis and AML. A Lysosomes play important roles in HSC maintenance and during cell division their
asymmetric inheritance can influence cell fate. B Lysosomes are enlarged in AML cells and these can sequester therapeutic drugs to promote
chemoresistance. C The various agents designed to target lysosomes in AML lead to five main consequences: (i) disruption of lysosome
membranes, leading to release of luminal enzymes into the cytosol to cause LCD, (ii & iv) hyper- or hypo-acidification of the lysosomal lumen
which disrupts lysosome function and can increase susceptibility towards certain drugs, (iii) alteration of luminal lipid profiles leading to
lysosome-dependent cell death, (iv) blocking activity of pumps or channels such as the vacuolar-type H+ATPase to reduce luminal acidity or
impair other lysosomal homeostasis, and (v) targeting various signaling proteins on the membrane surface to functionally impair lysosomes.
Created with BioRender.com.
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as an essential driver of leukemogenesis. Mechanistically, it does
so by activating mTORC1, thus, suppressing the ability of
autophagy to degrade the FLT3 protein [76]. In contrast, another
group found that FLT3-ITD upregulates basal autophagy mediated
by the transcription factor, ATF4 and inhibition of autophagy
could in fact, facilitate increased survival of mice with FLT3-ITD
driven AML [77]. The aforementioned examples aptly demonstrate
that, while the relevance of autophagy in AML is undeniable,
inconsistencies between results exist possibly because the process
has different implications at different levels of leukemic
transformation.
Autophagy in myeloid differentiation
Several studies indicate that autophagy plays a key role in myeloid
differentiation. Macroautophagy is upregulated during colony-
stimulating factor-1 mediated monocyte-macrophage differentia-
tion and is necessary for cell survival as it can direct cells towards
differentiation in lieu of apoptosis [78, 79]. Mechanistically, it has
been shown that autophagy-mediated lipolysis is necessary for
neutrophil differentiation [80].
Granulocytic differentiation can be induced in the AML
subtype APL by treatment with all-trans retinoic acid (ATRA).
Autophagy can facilitate degradation of the PML-RARA onco-
protein in APL, but it is also important for differentiation of AML
cells that do not have a fusion protein [81, 82]. ATRA-induced
differentiation and autophagy were found to be dependent
upon upregulation of TFEB [83]. More recently, it was shown that
degradation of fatty acid synthase via ATRA-induced macroauto-
phagy activates lysosomal biogenesis and accelerates granulocytic
differentiation [84].
TARGETING LYSOSOMES IN AML THERAPY
The lysosome is clearly a multi-functional organelle and there may
be many ways to target it for therapeutic gain in leukemia.
Moreover, lysosomes in AML cells are bigger in size which could
make AML cells more susceptible towards lysosomal disruption
than normal cells [85]. Several studies have investigated areas
such as: direct structural damage, interference with pH or other
luminal homeostasis, blocking associated signaling or interference
with key trafficking events (Fig. 5). Similar to solid cancers,
lysosomes also sequester chemotherapeutic drugs and confer
resistance in AML [86]. Therefore, targeting lysosomes can not
only serve as a way to destroy AML cells while sparing normal
hematopoietic cells, but may also be a strategy to combat
chemotherapy resistance.
Structural damage
In 1994, Craig Rosenfeld demonstrated the antileukemic property
of the lysosomotropic compound phenylalanine methyl ester in
leukemic specimens derived from patients [87].
A screen of a library of 100 drugs showed that the anti-malarial
drug, mefloquine, is effective against AML cell lines as well as
leukemia patient samples. A gene set enrichment analysis carried
out in yeast identified genes associated with lysosomal functions
to be enriched in gene deletion strains that were sensitive to
mefloquine, indicating that mefloquine targets lysosomes. Meflo-
quine disrupts the lysosomal membrane of AML cells allowing the
release of cathepsins B and L, which results in cell death [85].
Another in silico screening assay of FDA-approved drugs identified
a distinct subset of cationic-amphiphilic antihistamines that
selectively killed AML cell lines and primary patient samples.
Their toxicity was associated with the simultaneous disruption of
both lysosomes and mitochondria which triggered both autop-
hagy and apoptosis [88]. High expression of p53 induced gene 7
(pig7), which encodes for the small integral membrane protein of
lysosome/late endosome (SIMPLE) was found to induce lysosomal
membrane permeabilization in AML cell lines and render them
more susceptible to chemotherapies such as VP16 and daunor-
ubicin [89].
Interference with pH or other aspects of luminal homeostasis
The compound, deoxysappanone B 7,4′-dimethyl ether (Deox B
7,4) was identified from a chemical screen of small molecules with
anti-leukemic activity. It is a microtubule inhibitor, which indirectly
increases lysosomal V-ATPase activity causing hyper-acidification.
This effect leads to lysosomal disruption and the death of AML
cells. Interestingly, AML cells were found to be more vulnerable to
Deox B 7,4, compared to normal hematopoietic cells [90].
Conversely, blocking lysosomal acidification via the V-ATPase
inhibitor Archazolid A also has anti-leukemic effect. Archazolid A
reduces the anti-apoptotic protein survivin which leads to cell
death [91]. Several small molecules known as cationic amphiphilic
drugs (CAD) are already used in the treatment of various disorders
and possess lysosomotropic properties [92]. CADs are defined
structurally by the presence of both a hydrophobic and
hydrophilic domain. Many antihistamines, antidepressents, and
even mefloquine are classified as CADs. A recent study has
reported that CADs can induce lysosome-dependent cell death in
various AML cell lines by altering the lipid profile within the
lysosomal lumen. The compounds tested were the following
antihistamines: desloratadine, ebastine, loratadine, astemizole,
and terfenadine; the antimalarials: chloroquine and mefloquine;
and the antidepressants: desipramine, penfluridol, and siramesine,
among which siramesine and terfenadine had the strongest
effects [93]. The flavonoid polyphenol, quercetin has also been
reported to induce lysosome-dependent cell death in leukemia
and is effective against multi-drug resistant HL60 cell lines [94].
Lysosomal associated signaling
Several mTORC1 inhibitors, including rapamycin and its analogous
(rapalogs) have been developed. Many second-generation inhibi-
tors have also been developed that target both mTORC1 and
mTORC2, or mTORC1 and PI3K. Phase I/II studies with rapalogs as
single agents in AML have been disappointing, whereas combina-
tion studies with chemotherapy have demonstrated some
promise [95]. Interestingly, the mTORC1/2 dual inhibitor
AZD2014 was found to reduce the pH of lysosomes in AML cells
and this enhanced the cytotoxicity of the antibody-drug conjugate
Gemtuzumab ozogamicin (GO) [96]. The use of an antibody
conjugate such as GO in AML is particularly appealing as most
AMLs express CD33. GO requires an acidic environment inside
lysosomes for hydrolysis of the linker molecule and cytocidal
activity. The mTORC1-associated protein, raptor, represents a
potential target in AML, as its ablation blocks leukemia progres-
sion. However, it does not affect leukemic stem cell (LSC) renewal
[97]. mTORC1 inhibition sensitizes the cells to lysine-specific
demethylase 1 inhibitors and triggers differentiation in MLL
leukemia [98]. The lysosomal membrane protein LAMP5 acts as an
autophagy suppressor and targeting it promotes autophagic
degradation of the MLL fusion protein, which extends survival
[99]. A novel ATRA derivative, 4-amino-2-trifluoromethyl-phenyl
retinate (ATPR) has demonstrated superior anti-cancer efficacy
against AML by inducing ferroptosis in AML cells through a
mechanism involving macroautophagy [100].
Other novel approaches
An innovative approach to target AML cells involved the
development of a biohybrid with a tumor-associated peptide
somatostatin and the photosensitizer ruthenium, named RU-SST.
The stomatostatin receptor type 2 (SSRT2) is expressed more
highly on AML cell lines and leukemic cells of patients with AML
compared to HSCs from healthy donors. Therefore, the biohybrid
more specifically targets AML cells. Interestingly, RU-SST localizes
within the lysosomes, indicating their involvement in the
eradication mechanism [101]. Non-thermal plasma (NTP) is a
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relatively new addition in the field of cancer therapy. It is a form of
ionized gas consisting of atoms and molecules in an excited state.
NTP has been shown to induce cell death in AML cell lines, HL60,
and KG-1 via lysosome inhibition [102].
Lysosomes can be utilized in a rather unique manner by
harnessing them as a biologically derived nano-carrier. Encapsula-
tion of cancer drugs within nano-carriers such as liposomes has
already been put into practice. Lysosomes, due to their robustness
within the biological environment and low immunogenic reaction
can serve as a suitable carrier. Yeast-derived lysosomes, engi-
neered to carry the anthracycline drug, daunorubicin, have
exhibited efficacy against the AML cell line, HL60 [103].
CONCLUSION AND PERSPECTIVES
This review highlights the variety of functions associated with
lysosomes and emphasizes their central role in maintaining
cellular homeostasis. It is hardly surprising that deregulation of
lysosomal structure and function can play a key role in malignant
diseases such as AML. Tumor-specific lysosomal alterations have
been identified, opening the possibility of targeting lysosomes as
a way to exert maximum effect on cancer cells while sparing
normal ones. To date, the cornerstone of chemotherapy treatment
in AML is the combination of cytarabine (Ara-C) with an
anthracycline and/or allogeneic stem cell transplantation. How-
ever, patients above the age of 65 respond poorly to such a taxing
treatment regime. On the other hand, targeted therapies, while
less strenuous, are usually not effective as a monotherapy [104]. In
the scope of this review, we have highlighted lysosomal functions
that may be targeted therapeutically and potentially convey a
synergistic effect when combined with other modes of targeted
therapies.
One major issue in the field of lysosomal research is that the
lysosome has become synonymous with its degradative func-
tions and more attention needs to be drawn towards the
lysosome as a signaling organelle. Importantly, targeting the
lysosome is independent of the molecular lesions in AML and is
not dependent upon the disruption of up-stream receptor-
mediated signaling events—for which resistance is inevitable.
New targeting or chemo-sensitizing strategies of this type would
therefore be extremely valuable. We hope that this review
reiterates the importance of studying lysosomes and reinforces
the growing interest in exploring its value as a therapeutic
target in leukemia.
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